TY - JOUR T1 - Treatment Sequence of Aromatase Inhibitors and Radiotherapy and Long-term Outcomes of Breast Cancer Patients JF - Anticancer Research JO - Anticancer Res SP - 4311 LP - 4314 VL - 34 IS - 8 AU - MAKOTO ISHITOBI AU - MIZUHO SHIBA AU - TAKAHIRO NAKAYAMA AU - KAZUYOSHI MOTOMURA AU - HIROKI KOYAMA AU - KINJI NISHIYAMA AU - YASUHIRO TAMAKI Y1 - 2014/08/01 UR - http://ar.iiarjournals.org/content/34/8/4311.abstract N2 - Background: The optimal sequence of radiotherapy (RT) and hormone therapy using aromatase inhibitors (AI) in patients with breast cancer treated with breast-conserving surgery is unclear. Several short-term analyses have shown that there are no differences in breast cancer outcomes according to the treatment sequence. However, long-term outcomes have not been reported. Patients and Methods: We retrospectively analyzed disease-free survival events in 315 consecutive breast cancer patients who underwent breast-conserving surgery, RT, and received adjuvant AI at our Institute between 2001 and 2009. We compared the outcomes between treatment sequences of AI and RT (concurrent vs. sequential). Results: With a median follow-up of 5.6 years, no significant differences between the 2 groups in terms of disease-free survival (unadjusted p=0.6; adjusted p=0.5) were observed. Conclusion: Similarly to previous short-term reports, AI administration after RT and AI concurrently with RT are both reasonable treatment options for early-stage breast cancer patients treated with breast-conserving surgery. ER -